Autoimmune diseases and Sjogren's syndrome - An autoimmune exocrinopathy

被引:90
作者
Fox, Philip C.
机构
[1] Sjogrens Syndrome Fdn, Bethesda, MD 20814 USA
[2] Carolinas Med Ctr, Dept Oral Med, Charlotte, NC 28203 USA
来源
ORAL-BASED DIAGNOSTICS | 2007年 / 1098卷
关键词
salivary glands; biomarkers; xerostomia; diagnosis and therapy of Sjogren's syndrome;
D O I
10.1196/annals.1384.003
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Autoimmune diseases include a diverse group of over 80 conditions. Sjogren's syndrome is the second most common autoimmune rheumatic disease, with an estimated prevalence in the United States of 2-4 million persons. There are prominent and consistent oral and dental findings in Sjogren's syndrome related to the autoimmune-mediated loss of normal salivary function. Additionally, nonoral clinical manifestations of Sjogren's syndrome include: dry eyes (with specific ocular surface changes termed keratoconjunctivitis sicca); other xeroses, such as dryness of the nose, throat, skin, and vagina; peripheral (and less frequently central) neuropathies; myalgias and arthralgias; thyroid disorders (particularly autoimmune thyroiditis); pulmonary disorders; renal disorders; and lymphoma. There is a significant (20- to 40-fold) increase in the incidence of malignant lymphoma, particularly in primary Sjogren's syndrome. Establishing the diagnosis of Sjogren's syndrome has been difficult in the light of its nonspecific symptoms (dry eyes and mouth), disagreement on diagnostic criteria, and a lack of both sensitive and specific laboratory markers. Many serum and salivary biomarkers for Sjogren's syndrome have been proposed although, to date, none has proven to be sufficiently specific for diagnostic purposes or has been well correlated with disease activity measures. Investigators have recently begun to apply modern genomic and proteomic approaches to identify candidate biomarkers in Sjogren's syndrome. The results of these investigations promise to provide a wealth of information on candidate biomarkers and possible etiopathological mechanisms underlying this disorder. Further, this information will improve clinical outcomes by fostering the design of new rational therapeutics and assisting in the monitoring of clinical disease.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 33 条
[1]  
[Anonymous], PROGR AUT DIS RES RE
[2]   Gene expression profiling in human autoimmunity [J].
Baechler, EC ;
Batliwalla, FM ;
Reed, AM ;
Peterson, EJ ;
Gaffney, PM ;
Moser, KL ;
Gregersen, PK ;
Behrens, TW .
IMMUNOLOGICAL REVIEWS, 2006, 210 :120-137
[3]   Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: A potential breakthrough diagnostic and individualized therapy-design tool [J].
Centola, M. ;
Frank, M. B. ;
Bolstad, A. I. ;
Alex, P. ;
Szanto, A. ;
Zeher, M. ;
Hjelmervik, T. O. ;
Jonsson, R. ;
Nakken, B. ;
Szegedi, G. ;
Szodoray, P. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2006, 64 (03) :236-242
[4]   LABIAL SALIVARY-GLAND BIOPSY IN SJOGRENS SYNDROME - ASSESSMENT AS A DIAGNOSTIC CRITERION IN 362 SUSPECTED CASES [J].
DANIELS, TE .
ARTHRITIS AND RHEUMATISM, 1984, 27 (02) :147-156
[5]  
DANIELS TE, 1992, RHEUM DIS CLIN N AM, V18, P571
[6]   Parallel detection of autoantibodies with microarrays in rheumatoid diseases [J].
Feng, YF ;
Ke, X ;
Ma, RS ;
Chen, P ;
Hu, GG ;
Liu, FZ .
CLINICAL CHEMISTRY, 2004, 50 (02) :416-422
[7]  
FORABOSCO P, 2006, GENES IMMUN 0914
[8]   Salivary enhancement therapies [J].
Fox, PC .
CARIES RESEARCH, 2004, 38 (03) :241-246
[9]   Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome [J].
Gottenberg, JE ;
Busson, M ;
Cohen-Solal, J ;
Lavie, F ;
Abbed, K ;
Kimberly, RP ;
Sibilia, J ;
Mariette, X .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :1050-1055
[10]   Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases [J].
Goules, Andreas ;
Tzioufas, Athanasios G. ;
Manousakis, Menelaos N. ;
Kirou, Kyriakos A. ;
Crow, Mary K. ;
Routsias, John G. .
JOURNAL OF AUTOIMMUNITY, 2006, 26 (03) :165-171